Johnson & Johnson is planning to expand its empire with a $16.6bn cash acquisition of Pfizer's over-the-counter brands.
Johnson & Johnson is planning to expand its empire with a $16.6bn cash acquisition of Pfizer's over-the-counter brands.
The acquisition, described as at a premium price, if approved by federal regulators in the US, would solidify Johnson & Johnson's domination of the consumer health market.
Analysts added that Pfizer's Visine eye drops may give Johnson & Johnson a platform to expand its eye-care business, currently focused on contact lenses.
